Assignee
MEDICENNA THERAPEUTICS INC
CA·11 granted patents·8 pending applications·27 citations·filing 2014–2025
Top patents by PatentIndex Score
19 records- 0193US11680090B2Interleukin-2 fusion proteins and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2020·Granted Jun 20, 2023·3 cites·17 claims
- 0288US10093708B2Interleukin-4 receptor-binding fusion proteins and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2014·Granted Oct 9, 2018·9 cites·19 claims
- 0387US10106592B2Interleukin-4 receptor-binding fusion proteins and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2014·Granted Oct 23, 2018·8 cites·16 claims
- 0486US10781242B2Interleukin-2 fusion proteins and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2014·Granted Sep 22, 2020·5 cites·28 claims
- 0582US11084856B2Interleukin-4 receptor-binding fusion proteins and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2018·Granted Aug 10, 2021·1 cites·12 claims
- 0680US11542312B2IL-2 superagonists in combination with anti-PD-1 antibodiesMEDICENNA THERAPEUTICS INC·Filed 2018·Granted Jan 3, 2023·1 cites·15 claims
- 0779US12503496B2Interleukin-4 receptor-binding fusion proteins and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2022·Granted Dec 23, 2025·0 cites·12 claims
- 0877US12338269B2IL-2 superagonists in combination with anti-PD-1 antibodiesMEDICENNA THERAPEUTICS INC·Filed 2022·Granted Jun 24, 2025·0 cites·10 claims
- 0975US2024067689A1Interleukin-2 fusion proteins and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1074US2026035427A1Il-2 superagonists in combination with anti-pd-1 antibodiesMEDICENNA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1173US2022048965A1Interleukin-4 receptor-binding fusion proteins and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1270US11352402B2Interleukin-4 receptor-binding fusion proteins and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2018·Granted Jun 7, 2022·0 cites·16 claims
- 1362US2025387474A1Uses and methods for il-2, il-13, and il-4 cytokine bifunctional moleculesMEDICENNA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1460US12404497B2Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereofMEDICENNA THERAPEUTICS INC·Filed 2019·Granted Sep 2, 2025·0 cites·11 claims
- 1556US2023405115A1Combination therapy of mdna55 and a vascular endothelial growth factor a (vegf-a)MEDICENNA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1656US2016271231A1Treating cancer stem cells using targeted cargo proteinsMEDICENNA THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 1755US2023365642A1Bifunctional superkines and uses thereofMEDICENNA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1854US12274735B2IL-4-fusion formulations for treatment of central nervous system (CNS) tumorsMEDICENNA THERAPEUTICS INC·Filed 2018·Granted Apr 15, 2025·0 cites·20 claims
- 1947US2022347268A1Il-4r as a biomarker in cancerMEDICENNA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when MEDICENNA THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →